We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$61.9M
Cap. Flow
+$39M
Cap. Flow %
7.48%
Top 10 Hldgs %
67.45%
Holding
38
New
8
Increased
6
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$22.4M
2
VRDN icon
Viridian Therapeutics
VRDN
+$12.7M
3
CVAC
CureVac
CVAC
+$10.7M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$9.36M
5
IMVT icon
Immunovant
IMVT
+$6.86M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.9M
2
CSTL icon
Castle Biosciences
CSTL
+$8.27M
3
LUNG icon
Pulmonx
LUNG
+$8.04M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.63M
5
VIR icon
Vir Biotechnology
VIR
+$7.37M

Sector Composition

Rank Sector Weight
1 Healthcare 79.19%
2 Miscellaneous 20.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.01B
$109M 20.81%
800,000
-300,000
-27% -$44.3M
AVIR icon
2
Atea Pharmaceuticals
AVIR
$468M
$55.8M 10.7%
903,688
-113,000
-11% -$7.63M
MDVL
3
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$40.9M 7.84%
58,416
– –
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$23.7M 4.55%
1,728,590
-38,850
-2% -$568K
SYRS
5
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$23.5M 4.5%
313,990
+49,740
+19% +$5.17M
FATE icon
6
Fate Therapeutics
FATE
$297M
$22.3M 4.27%
270,000
+10,000
+4% +$958K
NTRA icon
7
Natera
NTRA
$47.3B
$22.1M 4.24%
218,000
+30,000
+16% +$3.29M
NUVB icon
8
Nuvation Bio
NUVB
$2.39B
$20.9M 4.01%
+2,000,000
New +$22.4M
NTLA icon
9
Intellia Therapeutics
NTLA
$1.79B
$18.1M 3.46%
225,000
– –
RGEN icon
10
Repligen
RGEN
$9.46B
$16M 3.08%
82,500
– –
COGT icon
11
Cogent Biosciences
COGT
$6.03B
$14.2M 2.73%
1,622,591
– –
IOVA icon
12
Iovance Biotherapeutics
IOVA
$3.98B
$12.9M 2.47%
406,986
+46,986
+13% +$1.95M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.6B
$11.4M 2.18%
+680,768
New +$12.7M
ITOS
14
DELISTED
iTeos Therapeutics
ITOS
$11M 2.12%
322,794
– –
EPIX
15
DELISTED
ESSA Pharma
EPIX
$10.6M 2.02%
363,185
+285,000
+365% +$6.62M
ORIC icon
16
Oric Pharmaceuticals
ORIC
$1.33B
$10.1M 1.94%
413,061
– –
CVAC
17
DELISTED
CureVac
CVAC
$10.1M 1.93%
+110,000
New +$10.7M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$9.87M 1.89%
230,000
– –
BOLT icon
19
Bolt Biotherapeutics
BOLT
$7.51M
$9.47M 1.82%
+14,386
New +$9.36M
APTO
20
DELISTED
Aptose Biosciences, Inc.
APTO
$8.42M 1.61%
3,131
– –
OLK
21
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$7.2M 1.38%
+200,000
New +$6.74M
ARVN icon
22
Arvinas
ARVN
$614M
$6.89M 1.32%
104,253
+4,253
+4% +$325K
CSTL icon
23
Castle Biosciences
CSTL
$1.01B
$6.85M 1.31%
100,000
-110,000
-52% -$8.27M
ITMR
24
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$6.55M 1.26%
273,569
-228,395
-46% -$5.43M
FDMT icon
25
4D Molecular Therapeutics
FDMT
$827M
$6.51M 1.25%
150,000
– –
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q1 2021 Portfolio in Review

As of Q1 2021, Ally Bridge Group held 38 positions worth $522M, down 11% from $584M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Ally Bridge Group deployed $39M of net new capital in Q1 2021, opening 8 new positions and adding to 6 existing holdings. Its largest new stake was Nuvation Bio: 2,000,000 shares worth $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Castle Biosciences, an estimated $8.27M trimmed.

  • Ally Bridge Group's largest Q1 2021 buy was Nuvation Bio: 2,000,000 shares worth $20.9M.
  • Ally Bridge Group added most to ESSA Pharma in Q1 2021, an estimated $6.62M increase.
  • Ally Bridge Group's biggest Q1 2021 reduction was Castle Biosciences, cutting an estimated $8.27M.
  • Ally Bridge Group fully exited Aurinia Pharmaceuticals in Q1 2021, selling an estimated $11.9M.
  • Ally Bridge Group's ten largest holdings make up 67% of its $522M portfolio in Q1 2021.
  • Ally Bridge Group opened 8 new positions and closed 6 in Q1 2021.
  • Ally Bridge Group's portfolio value fell 11% quarter-over-quarter to $522M.

Based on Ally Bridge Group's 13F filing for Q1 2021, filed 17 May 2021.